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Abstract
Diphenyl diselenide (PhSe)2, a simple organoselenium compound, possesses interesting pharmacological properties that
are under extensive research. As macrophages respond to microenvironmental stimuli and can display activities engaged
in the initiation and the resolution of inflammation, in the present report we describe the ability of (PhSe)2 to modulate
the macrophage activation. Our data indicate that (PhSe)2 could inhibit the NO production in a dose-dependent fashion
in peritoneal macrophages activated by LPS or treated with vehicle alone. We could demonstrate that this effect
correlated with a reduction in the expression of the inducible NO synthase in (PhSe)2-treated cells. Furthermore,
(PhSe)2 suppressed the production of reactive oxygen species, diminished the activity of the arginase enzyme, and the
accumulation of nitrotyrosine modified proteins in LPS-stimulated macrophages. This compound also diminished the
antigen presentation capacity of classically activated macrophages, as it reduced MHCII and CD86 expression. In addi-
tion, (PhSe)2 modulated the alternative activation phenotype of macrophages. Dexamethasone-activated macrophages
presented higher production of IL-10 and CD206, which were both down-regulated by the addition of (PhSe)2. These
results suggest that (PhSe)2 possesses antioxidant and anti-inflammatory activities in classically-activated macrophages.
We could demonstrate that (PhSe)2 can be also utilized to modulate the alternative activation phenotype of
macrophages.
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Introduction
Macrophages (Mph) represent a population of cells
with marked phenotypic heterogeneity. They can be
involved in both the initiation and the resolution of
inflammation because of their ability to respond to sig-
nals they receive from the microenvironment. Mph
have been categorized into subsets in analogy to the
dichotomous Th1 and Th2 classification of T lympho-
cytes. Classically activated Mph (CaMph) or M1 Mph
are generated following stimulation with microbial
products and Th1 cytokines. Activation of macro-
phages to the M1 phenotype leads to enhanced micro-
bicidal capacity and high secretion of pro-inflammatory
cytokines (TNF-a, IL-1, IL-6, IL-12 and IL-23), thus
polarizing a type I response. These cells are associated
with augmented expression of MHCII and co-stimula-
tory molecules (CD86), and enhanced antigen-present-
ing capacity.1 CaMph produce high levels of oxidative
metabolites, NO and reactive oxygen species (ROS) to
increase their killing activity.2 CaMph have been impli-
cated in several autoimmune pathologies, such as mul-
tiple sclerosis3, orchitis4 and rheumatoid arthritis5, and
in chronic inflammation-associated processes, such as
obesity and atherosclerosis.6,7
Inflammatory processes triggered during infection
are critical for pathogen removal. However, an exces-
sive or prolonged inflammatory response is deleterious
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for the host, and must be stopped to allow healing.
Mph also undergo alternative activation when stimu-
lated with IL-4 or IL-13 (AaMph or M2 Mph), and
represent a population involved in tolerance and the
resolution of inflammation. These cells can be found
in wound healing8, human term placenta9 and in the
lung.10 AaMph are generated in pathologies that
involve a Th2 profile, like parasitic infections, asthma
and allergy.11 These cells can function as modulators of
the immune response given that IL-4 stimulates the
production of anti-inflammatory cytokines (IL-10 and
IL1-RA) while inhibiting the expression of pro-inflam-
matory cytokines. Several phenotypic markers have
been identified for M2 Mph, such as Ym1 and Ym2,
Found in Inflammatory Zone (FIZZ) 1 and Mph man-
nose receptor (CD206).12 Th2-mediated induction of
arginase I (Arg1) is a general feature of murine
AaMph. This enzyme hydrolyzes L-arginine, the
common substrate for both cytokine-inducible nitric
oxide synthase (iNOS) and Arg1, to urea and
L-ornithine, which is used to produce polyamines and
proline to promote cell growth and collagen
production.13
Despite the fact that the concept of AaMph was
originally created to specifically distinguish the popula-
tion of cells activated in the presence of IL-4 or IL-13, it
was broadened to consider the phenotype of Mph acti-
vated by another set of stimuli that share properties
involved in type II responses. To distinguish between
the different, but overlapping, populations it has been
proposed that the Mph activated by IL-4/IL-13 should
be named M2a, M2b should be used to refer to Mph
stimulated by immune complexes and TLR agonists
and Mph treated with IL-10 or glucocorticoids should
be named M2c. In particular, M2b Mph are character-
ized by high levels of production of IL-10 and low levels
of IL-12. They better resemble the M1 population, as
they produce pro-inflammatory cytokines, they do not
induce Arg1 or FIZZ, and retain the ability to present
antigens.14 On the other hand, M2c Mph present a
deactivated phenotype, they switch off the production
of pro-inflammatory cytokines and reactive species
(NO and ROS), down-regulate the expression of
MHC class I and II expression and antigen
processing.15
Considering that the activation of pro-inflammatory
situations is strictly related to ROS generation, and
both circumstances are involved in several pathologies,
increasing attention has focused on the development of
new drugs with antioxidant/anti-inflammatory proper-
ties. In this way, several organoselenium compounds
are proposed as promising antioxidant and anti-inflam-
matory agents. In this scenario, we have been studying
the pharmacological properties of diphenyl diselenide
(PhSe)2, a simple diaryl diselenide whose biological
activities can be explained by the in vivo metabolism
to selenol intermediates. (PhSe)2 and some of its
analogs have high GPx-mimetic activity16 and can
also be substrates for rat hepatic and cerebral thio-
redoxin reductase (TrxR).17–18 Consequently, subtle
changes in the aryl moiety of diselenides can be used
as a tool for dissociation of GPx or TrxR pathways as
mechanism triggering their antioxidant activities. In
fact, (PhSe)2 has proven to be an anti-inflammatory
agent in the carragenin-induced paw edema model.19
In line with this, we recently demonstrated that
(PhSe)2 reduced the atherosclerotic lesion in hyper-
cholesterolemic mice by modulating pathways related
to antioxidant and anti-inflammatory responses.20
Moreover, it has been demonstrated that another
diaryl diselenide compound, bis-(3-hydroxyphenyl) dis-
elenide, was able to reduce the expression of iNOS,
COX-2, TNF-a, IL-1b and IL-6 through the down-
regulation of NF-kB binding activity.21
Bearing in mind that ROS regulate redox-sensitive
transcription factors which transcribe various inflam-
matory genes22, and that (PhSe)2 possesses antioxidant
properties, it could be attractive to explore its anti-
inflammatory properties. In this study, we aimed to
explore the pharmacological properties of (PhSe)2 in
cultured peritoneal Mph and how it can modulate the
different activation pathways of these cells. Our results
indicate that (PhSe)2 significantly inhibited the produc-
tion of NO and ROS in activated Mph, as well as
the immune content of iNOS and nitrotyrosine.
Furthermore, (PhSe)2 treatment induced a reduction
in the percentage of MHCII+ and CD86+ cells, and
also diminished the activity of Arg1. Regarding the
effects on M2c Mph, (PhSe)2 treatment inhibited the




(PhSe)2 was synthesized according to published meth-
ods. Analysis of the 1H-NMR and 13C-NMR spectra
showed that the obtained compound presented ana-
lytical and spectroscopic data in full agreement
with its assigned structure. The chemical purity of
(PhSe)2 (99.9%) was determined by GLC/HPLC.
23
RPMI 1640 modified medium without phenol red,
phorbol 12-myristate 13-acetate (PMA), LPS
from Escherichia coli serotype O111:B4, 20,70-dichloro-
fluorescein diacetate (DCF-DA), and aminoguanidine
were from Sigma-Aldrich (St Louis, MO, USA).
Dexamethasone was from SIDUS (Vicente López,
Argentina). Recombinant rat IFN-g, anti-CD86
(OX-48) conjugated to biotin, anti-MHCII (OX-6)
conjugated to FITC, and anti-CD206 (MR5D3) con-
jugated to FITC were from AbD Serotec
(Raleigh, NC, USA). Allophycocyanin-conjugated
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streptavidin was from eBioscience (San Diego, CA,
USA). FBS and RMPI 1640 medium were from
GBO (Córdoba, Argentina). Anti-iNOS polyclonal
Ab was from BD (Franklin Lakes, NJ, USA).
IRDye 800CW anti-mouse IgG and IRDye 800CW
anti-rabbit IgG Abs were from LICOR (Lincoln,
NE, USA). Anti-b actin Ab was from Developmental
Studies Hybridoma Bank (Iowa City, IA, USA). Anti-
nitrotyrosine Ab was kindly provided by Dr Carlos A.
Arce (UNC, Córdoba, Argentina). The rest of the
chemical reagents were analytical-grade of the highest
purity available.
Animals
Albino six- to eight-week-old rats from a Wistar strain
inbred in our laboratory for 40 years were used. All
animal care and use was in accordance with the
National Institutes of Health regulations and the
Institutional Care and Use of Animals Committee
(exp. No. 15-99-40426) approved animal handling and
experimental procedures. Every effort was made to
minimize both the number of animals used and their
suffering.
Isolation of peritoneal Mph
Normal resident peritoneal cells were obtained by a
peritoneal washing with 20ml Dulbecco’s PBS contain-
ing 2% FBS and 40 mg/ml gentamicin. After centrifu-
gation at 350 g for 5min, red blood cells were lyzed in
ACK buffer and mononuclear cells were re-suspended
in complete medium (RPMI 1640, 10% FBS, 40 mg/ml
gentamicin) and incubated at 37 C for 120min in plas-
tic culture plates. Then, the non-adherent cells were
removed, and the adherent cells were cultured in com-
plete medium with different stimuli.24 For viability,
nitrite and ROS production, flow cytometry, arginase
activity and IL-10 production 106 cells/well were cul-
tured in a volume of 1ml. For iNOS and nitrotyrosine
immunodetection 3 106 cells/well were cultured in
a volume of 2ml. The cells were treated with the
following drugs: 0.5mg/ml LPS, 2.5–20 mM (PhSe)2,
10 ng/ml IFNg, 1.5mM dexamethasone or 1mM
aminoguanidine.
Quantification of nitrite in culture supernatants
Supernatants from Mph which had been cultured for
48 h with or without the indicated stimuli were ana-
lyzed. The concentration of nitrites was assayed in
duplicate by a standard Griess reaction adapted to
microplate as an indirect measurement of NO synthesis.
The absorbance at 550 nm was obtained with a micro-
plate reader model 680 (Bio-Rad Laboratories,
Hercules, CA, USA). The data were referred to a stan-
dard curve of sodium nitrite.25
Measurement of ROS production
Mph which had been cultured overnight (16–18 h) with
or without different concentrations of (PhSe)2 were har-
vested and incubated simultaneously with 100 ng/ml
PMA and the ROS probe DCF-DA (2mM) for 1 h at
37 C. Then, the cells were washed twice with PBS and
the fluorescence intensity was analyzed by flow cytom-
etry in a FACSCanto II (BD).26 The fluorochrome
DCF-DA was excited by the 488-nm laser and the fluo-
rescent emission was obtained by the 530/30 filter of the
flow cytometer.
iNOS and nitrotyrosine Western blotting
Peritoneal Mph which had been cultured for 24 h (for
immunodetection of iNOS) or 48 h (for immunodetec-
tion of nitrotyrosine) with 5 mM (PhSe)2, 1mM amino-
guanidine and/or 0.5 mg/ml LPS were harvested and
lyzed with 50 ml of 0.5% Triton X-100. The solution
was then centrifuged at 4 C at 10,000 g, and protein
concentration was determined by the Bradford assay
(Biorad, Hercules, CA, USA). Equal amounts of protein
(40 mg/lane) were separated in 10% SDS-PAGE and
electrotransferred to a nitrocellulose membrane (GE
Healthcare, Piscataway, NJ, USA). The membranes
were blocked in PBS with 3% skim powered-milk and
incubated overnight with the primary Abs.27 Then, the
membranes were washed thoroughly and incubated with
a secondary Ab, IRDye 800CW anti-mouse IgG and
IRDye 800CW anti-rabbit IgG for 1 h at room temper-
ature (20–24 C). Immunodetection was performed with
the Odyssey Infrared Imaging System (LICOR,
Lincoln, NE, USA). The immunoreactive protein
bands were analyzed with the Gel-Pro Analyzer soft-
ware (Media Cybernetics Inc., Bethesda, MD, USA).
Flow cytometry
Peritoneal Mph which had been cultured for 24 h with
different stimuli were harvested and stained with the
following reagents for surface activation markers:
MHC-II, CD86 and CD206. Appropriate isotype con-
trols were used. The cells were analyzed in a
FACSCanto II.
Measurement of Arg1 activity
To analyze the Arg1 activity of cultured Mph, the cells
were harvested and lyzed with 100 ml 0.2% Triton
X-100. Then, 50 ml of the lysate was incubated with
50 ml of 10 nM MnCl2 and 50 ml 50mM Tris-HCl (pH
7.5) for 10min at 56 C to induce the activation of the
enzyme. Arginine hydrolysis was conducted by incubat-
ing the samples with 100 ml 0.5M L-arginine (pH 9.7) at
37 C for 60min. The enzymatic reaction was stopped
by adding 900 ml of a mixture of H2SO4 (96%)/H3PO4
(85%)/H2O (1:3:7 v/v/v). To determine the content of
Rupil et al. 629
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urea 40 ml of 9% isonitrosopropiophenone (dissolved in
100% ethanol) were added and the samples were heated
at 95 C for 45min, then the absorbance at 550 nm was
measured with a model 680 microplate reader (Bio-Rad
Laboratories).28 A standard curve of urea was used to
calculate urea content and the results are expressed as
mg urea/mg proteins.
Measurement of IL-10
Cytokine secretion was determined in supernatants col-
lected from Mph which had been cultured for 48 h with
the indicated stimuli. The concentration of IL-10
was measured using matching antibodies in a
sandwich ELISA according to the indications of the
manufacturer.
Statistical analyses
The results are presented as mean standard error of
the mean (SEM). Comparisons between groups were
performed by analysis of variance (ANOVA) followed
by LSD Fisher test when appropriated. P values less
than 0.05 (P< 0.05) were considered as indicative of
significance. Linear regression analysis was also used
to test dose-dependent effects.
Results
Effect of (PhSe)2 on cell viability and LPS toxicity
The effect of (PhSe)2 on the viability of Mph is pre-
sented in Figure 1. We evaluated the toxicity of this
compound by means of the Trypan blue exclusion
assay. A two-way ANOVA of the percentage of
viable cells yielded a significant effect of the addition
of both, LPS and (PhSe)2, and LPS (PhSe)2 interac-
tion. Post hoc comparisons demonstrated that (PhSe)2
did not affect the viability of unstimulated cells at con-
centrations of 2.5 and 5 mM. However, at concentra-
tions equal to or higher than 10 mM it diminished the
percentage of viable cells. This toxic effect has been
attributed to the reduction of biologically important
thiols. On the other hand, we observed that LPS
induced a decrease in the percentage of viable cells. In
contrast to the unstimulated cells, the addition of
(PhSe)2 did not diminish the viability of the LPS-trea-
ted cells. In fact, at a concentration of 5 mM, (PhSe)2
partially prevented the macrophage cell death induced
by LPS which could be caused by the reduction of toxic
species produced by activated Mph.
(PhSe)2 modulates NO production and iNOS
expression
In order to analyze the anti-inflammatory properties of
(PhSe)2, we assessed whether this compound can
regulate the production of NO. Mph were cultured for
48 h and then theNO production in culture supernatants
was determined by the Griess reaction. At basal state,
the addition of (PhSe)2 induced a dose-dependent
decrease in the nitrites production [F(1,16)¼ 5.22;
P< 0.05; b¼0.50]. Aminoguanidine, a selective inhib-
itor of the iNOS enzyme, was used as a positive control
(Figure 2A). As expected, the exposure of Mph to LPS
induced a great NO production. Statistical analysis of
the concentration of NO in cells activated by LPS
revealed a significant effect of (PhSe)2. Interestingly,
(PhSe)2 displayed a concentration-dependent inhibitory
effect toward the NO production in culture supernatants
[F(1,26)¼ 29.25; P< 0.001; b¼0.73] (Figure 2B).
Western blot analyses were performed to determine
whether the inhibitory effect of (PhSe)2 on NO produc-
tion is related to its modulation of iNOS. A two way
ANOVA of the iNOS/actin ratio revealed a significant
effect of (PhSe)2 and LPS. In unstimulated Mph, we
found that the addition of (PhSe)2 induced a statisti-
cally significant decrease in the amount of iNOS.
Moreover, the expression of iNOS proteins was
induced by LPS, and the treatment with (PhSe)2 inhib-
ited this up-regulation (Figure 2C).
(PhSe)2 diminishes the ROS production
Next, we sought to further characterize the antioxidant
properties of (PhSe)2 by evaluating the ROS produc-
tion by means of the intracellular fluorescent probe
DCF-DA. We stimulated the cells in the presence or
absence of PMA to induce the production of ROS
and increasing concentrations of (PhSe)2. Statistical
analysis by two way ANOVA of the mean fluorescence
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Figure 1. Effect of (PhSe)2 on the viability of macrophages.
Peritoneal macrophages were cultured for 48 h and treated with
increasing concentrations of (PhSe)2; concomitantly, the cells
were activated or not with LPS. The cells were dyed with Trypan
blue to determine their viability. Data indicate the percentage of
viable cells and are presented as mean SEM of six independent
experiments (n¼ 6). Significant differences of treated groups with
respect to control without (PhSe)2 and LPS are indicated by
*P< 0.05, **P< 0.01, ***P< 0.001.
630 Innate Immunity 18(4)
 at MINCYT on July 23, 2012ini.sagepub.comDownloaded from 
PMA and a PMA (PhSe)2 interaction. We found that
the addition of (PhSe)2 to Mph in the basal state dimin-
ished ROS production in a dose dependent manner
[F(1,33)¼ 24.48; P< 0.001; b¼0.65]. The post hoc
LSD Fisher test (Figure 3) showed that, as expected,
PMA exposure significantly increased ROS generation,
while the treatment with (PhSe)2 in all concentrations
tested decreased ROS production in PMA-stimulated
cells. Interestingly, (PhSe)2 caused a concentration-
dependent inhibition of the MFI in these activated
Mph [F(1,33)¼ 62.79; P< 0.001; b¼0.81].
(PhSe)2 diminishes nitrotyrosine formation
Peroxynitrite (ONOO.), the reaction product of NO
and superoxide radicals, is a potent oxidant that has
been implicated as a pathogenic mediator in a variety
of disease conditions. Indeed, under appropriate stim-
ulation conditions, immune cells, and, most notably
Mph, can produce substantial amounts of peroxyni-
trite as a result of the iNOS and NADPH oxidase-
dependent formation of NO and O2, respectively.
Peroxynitrite promotes nitration (incorporation of a
NO2 group) of aromatic and aliphatic protein resi-
dues. Most notably, protein tyrosine residues consti-
tute key targets for peroxynitrite-mediated nitration
and the presence of 3-nitrotyrosine in proteins repre-
sents a usual modification introduced by the biological
formation of peroxynitrite.29 To study tyrosine nitra-
tion, peritoneal Mph were isolated and stimulated
in vitro for 48 h with LPS and either vehicle or 5 mM
(PhSe)2. Given that nitration of proteins by peroxyni-
trite occurs as a specific but multi-target phenomenon,
we quantified the intensity of all the bands that
appeared on the nitrocellulose membrane and used
the data of intensity of the entire lane to perform
the statistical analysis. The results presented in
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Figure 2. (PhSe)2 modulation of NO production and iNOS expression. (A) Peritoneal macrophages were cultured for 48 h in the
absence (A) or presence (B) of LPS and then treated with increasing concentrations of (PhSe)2 or 1 mM aminoguanidine (AG). The
supernatants were collected and the nitrite concentration was determined by the Griess assay (n¼ 6). (C) Mph were cultured with or
without LPS and/or 5 mM (PhSe)2, then the cells were collected and Western blot analyses were performed to determine the amount
of iNOS (n¼ 9). Significant differences of treated group with respect to 0mM (PhSe)2 are *P< 0.05, **P< 0.01, ***P< 0.001.
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nitrotyrosine when the cells were exposed to LPS
compared with untreated controls. The addition
of (PhSe)2 prevented the increase in nitrotyrosine
in LPS-treated cells. Aminoguanidine was used as pos-
itive control as it causes an inhibition in protein nitra-
tion (Figure 4).
(PhSe)2 diminishes the expression of MHCII and
costimulatory molecules
The effect of (PhSe)2 on the expression of co-stimula-
tory molecules and MHCII on the surface of Mph was
examined by flow cytometry. To test whether expres-
sion of these molecules is modulated by (PhSe)2, the
cells were treated with IFN-g+LPS and the seleno-
organic compound, and after about 18 h of culture,
the cells were double labeled with anti-MHCII and -
CD86 mAbs and analyzed by flow cytometry.
According to a two way ANOVA, both (PhSe)2 and
IFN-g+LPS had a significant effect on the expression
of CD86. Classical activation of Mph enhanced CD86
expression (130 13% with respect to control,
P< 0.01), whereas the addition of 5 mM (PhSe)2 inhib-
ited this up-regulation (88 4% respect to control,
P< 0.001 with respect to IFN-g+LPS). Furthermore,
the addition of (PhSe)2 modulated the basal levels of
CD86 inducing a reduction of 22% respect to control
(P< 0.05).
A two-way ANOVA of the percentage of
MHCII+cells revealed a significant effect of the addi-
tion of (PhSe)2 and IFN-g+LPS. Treatment with
IFN-g+LPS augmented the percentage of MHCII+
Mph by 30% (P< 0.001) with respect to vehicle-treated
cells. A reduction in MHCII expression was observed
after treatment with (PhSe)2 in basal state-Mph and
CaMph, 48 4% (P< 0.001 respect to control) and
61 5% (P< 0.001 respect to IFN-g+LPS), respec-
tively (Figure 5B).
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Figure 4. Effect of (PhSe)2 on the immunocontent of nitrotyrosine in peritoneal macrophages lysates. Mph were cultured for 48 h
with or without 0.5 mg/ml LPS and 5 mM (PhSe)2. Homogenates of the cells were probed for nitrotyrosine by SDS-PAGE and
immunoblotting using an Ab raised in rabbits against nitro-keyhole limpet hemocyanin (KLH). The intensity of all the bands that
appeared on the nitrocellulose membrane were quantified to perform the statistical analysis. The cells were treated with vehicle (lane
1), (PhSe)2 (lane 2), LPS (lane 3), LPS and (PhSe)2 (lane 4), or LPS plus aminoguanidine (AG) (lane 5). The blot shown is representative
of three independent experiments (n¼ 7). Significant differences are *P< 0.05, **P< 0.01.
10000
















0 2.5 5 10 20
– – – – –
0 2.5 5 10 20
+ + + + +
Figure 3. Effect of (PhSe)2 on the production of ROS in PMA-
stimulated Mph. Peritoneal Mph were cultured for 24 h with
different concentrations of (PhSe)2 and treated for 2 h with or
without PMA. The production of ROS was assessed by incubating
the cells with DCF-DA and analyzing them by flow cytometry.
Data indicate the MFI and are presented as mean SEM of three
independent experiments (n¼ 8). Significant differences are
indicated by *P< 0.05, **P< 0.01, ***P< 0.001 with respect to
0mM (PhSe)2; . ###P< 0.001 with respect to 0mM (PhSe)2 plus
PMA.
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(PhSe)2 modulates the activity of Arg1
NO produced by Mph is toxic to host tissues and invad-
ing pathogens and its regulation is therefore essential to
suppress host cytotoxicity. Mph Arg1 inhibits the pro-
duction of NO by competing with NO synthases for
arginine, the common substrate of NO synthases and
arginases. Distinct mechanisms regulate Arg1 expres-
sion;30 AaMph require the functions of both STAT6
and C/EBPb, but are independent of MyD88. In con-
trast, expression of Arg1 induced by mycobacteria is
independent of the STAT6 pathway but depends on
C/EBPb and MyD88. These data are consistent with
studies documenting the induction of Arg1 expression
by LPS. In order to analyze whether (PhSe)2 could
modulate the activity of the Arg1 enzyme, Mph were
cultured with this compound, then the cells were
collected and Arg1 activity was determined in cell
lysates by a colorimetric method. Statistical analysis
by one way ANOVA of the Arg1 activity in cells cul-
tured in the absence of LPS did not reveal a significant
effect of the presence of (PhSe)2 (Figure 6A). On the
other hand, in LPS-treated Mph, Arg1 activity revealed
a significant concentration-dependent effect of the addi-
tion of (PhSe)2 (F(1,43)¼ 14.52; P< 0.001; b¼0.50).
The presence of 20 mM (PhSe)2 caused a 57% decrease
in enzymatic activity, whereas the other concentrations
tested did not modify the urea content in a statistically
significant way (Figure 6B).
(PhSe)2 diminishes the expression of CD206 and the
production of IL-10 in Mph activated by
dexamethasone
Taking into account that (PhSe)2 presented several
properties as an anti-inflammatory compound, we
sought to evaluate if it could also modulate the alter-
native activation of Mph. For that purpose, peritoneal
Mph were cultured with 1.5mM dexamethasone con-
comitant to the addition of 5 mM (PhSe)2. The cells
were collected and the surface expression of CD206,
an alternative activation marker was assessed by flow
cytometry. A two way ANOVA of the percentage of
CD206+ Mph showed a significant effect of (PhSe)2
and dexamethasone. The expression of CD206 was
significantly higher in dexamethasone-treated cells
(136 11% of the control, P< 0.01), whereas the addi-
tion of (PhSe)2 inhibited this up-regulation (101 7%,
P< 0.01 respect to dexamethasone) (Figure 7A). To
further assess the ability of (PhSe)2 to modulate the
phenotype of dexamethasone-activated Mph, we per-
formed an ELISA to determine the production of
IL-10 in culture supernatants. A two way ANOVA
of the concentration of IL-10 showed a significant
effect of the addition of dexamethasone. The cells in
the basal state secreted 219 47 pg/ml of IL-10 and
the (PhSe)2 treated cells 202 15 pg/ml. The addition
of dexamethasone induced an augmentation of the con-
centration of IL-10 (506 63 pg/ml), while the concom-
itant treatment with (PhSe)2 diminished the IL-10 levels
(331 77 pg/ml) (Figure 7B).
Discussion
The biological importance of selenium led to the devel-
opment of pharmacologically active organoselenium
compounds, among them (PhSe)2, whose biological
activities have begun to be studied and it has become
a good candidate for therapeutic purposes.16–21 In the
present study, we aimed at deepening the knowledge of
the properties of (PhSe)2 in a model of Mph polariza-
tion. We found that (PhSe)2 was able to modulate Mph



































































Figure 5. (PhSe)2 modulation of the expression of MHCII and
CD86 in classically-activated Mph. Purified peritoneal Mph were
treated in vitro with IFN-g (10 ng/ml) plus LPS (0.5 mg/ml) to
acquire the classical activation phenotype and 5 mM (PhSe)2. The
cells were stained for CD86 and MHCII and expression was
evaluated by flow cytometry. The surface expression of (A)
CD86 and (B) MHCII are shown as percentage respect to con-
trol. Data are presented as mean SEM of two independent
experiments (n¼ 4). Significant differences are indicated by
*P< 0.05, **P< 0.01, ***P< 0.001.
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of pro-inflammatory mediators and the markers of
alternative activation.
The role of ROS in inflammatory disorders has been
the subject of intensive investigation. During the
inflammatory process, activated immune cells increase
the expression of cytokines, chemokines, ROS and NO,
that amplify and perpetuate the inflammation. ROS
and NO are known to directly affect macromolecules,
producing a modification and possibly affecting their
function. It means that ROS and NO can be responsi-
ble for the cellular damage that is present in inflamma-
tion. Nevertheless, ROS may play a role in enhancing
inflammation through the activation of redox-sensitive
transcription factors, such as the NF-kB and the acti-
vator protein-1. This resulted in an increased expression
of a battery of distinct pro-inflammatory mediators.22
Therefore, considerable effort has been deployed in the
search for low-toxicity scavengers and inhibitors of
ROS. To identify and characterize the properties of
(PhSe)2 in cultured Mph, we analyzed the production
of ROS in presence of an increasing concentration of
this compound. We could demonstrate that (PhSe)2 effi-
ciently inhibited ROS production, either via substrate
for TrxR or because of the mimicking of the endoge-
nous antioxidant enzyme, GPx.16–18 In line with this, a
recent study showed that in vitro (PhSe)2 pretreatment
decreased the generation of ROS in J774 Mph when
exposed to oxidized low-density lipoprotein.20 Our
group has also investigated the potential of (PhSe)2 to
modulate the release of NO, an important inflamma-
tory product involved in the killing of microorganisms,
as well as tissue damage when overproduced. (PhSe)2
inhibited the production of NO from Mph activated
with LPS. Furthermore, this was related to the ability
of this organoselenium compound to down-modulate
the iNOS content. Consistent with this finding is the
effect of diaryl diselenides in the suppression of NO
production in RAW 264.7 Mph.21 It was also described
that (PhSe)2 can down-regulate the expression of iNOS
in brain slices submitted to glucose and oxygen
deprivation.31
Antigen presentation is a crucial process during
immunity for the generation of protective T-cell
responses against pathogens or other foreign structures.
The ‘professional’ antigen-presenting cells equipped to
initiate a primary immune response by the presentation
of antigen to naı̈ve T cells are dendritic cells and Mph.
After exposure to microbial products or inflammatory
stimuli, these cells undergo an activation program that
induces major phenotypic and functional modifica-
tions, especially affecting antigen capture, processing,
and MHCII trafficking. Furthermore, maturation
coincides with an increase in the expression of co-sti-
mulatory signals required for efficient priming. In the
present study, we found that the treatment with (PhSe)2
inhibited the surface expression of both, MHCII and
CD86 molecules, and that this compound also pre-
vented the augmentation induced by IFN-g+LPS.
These observations suggest that (PhSe)2 may serve as
a compound used to prevent unwanted activation of
T-cell responses. In accordance with our results,
Matsue et al.32 found that Ebselen at 10–20mM effi-
ciently inhibited LPS-induced CD86 up-regulation in
bone marrow-derived dendritic cells, and this was
accompanied by suppression in antigen-specific, den-
dritic cells-dependent proliferation by DO11.10T cells
in a dose-dependent manner. Furthermore, there are
some reports that evaluate the role of selenium intake
in antigen presentation. In this respect, it was found
that low selenium intake could weaken the ability of
recognizing and presenting OVA antigen by peritoneal
macrophages of Wistar rats.33
On the other hand, alternative activation of Mph
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Figure 6. Effect of (PhSe)2 on the Arg1 activity in LPS treated Mph. Arg1 activity was measured in cell lysates from macrophages
cultured in the absence (A) or presence (B) of LPS (0.5 mg/ml) for 48 h. Data indicate the concentration of urea normalized to protein
content and are presented as mean SEM of six independent experiments (n¼ 6). **P< 0.01 with respect to 0 mM (PhSe)2.
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including low production of pro-inflammatory cyto-
kines, ROS and NO, and abundant levels of non-opso-
nic receptors. Until recently, the discrimination
between CaMph and AaMph in mice was mainly dem-
onstrated at the biochemical level, in the metabolism of
L-arginine. The arginase pathway predominates in M2
Mph; this enzyme hydrolyzes L-arginine to L-ornithine
and urea.11 In mammals, there are two isoen-
zymes—the isoform Arg1 is expressed in the liver as
one of the enzymes of the urea cycle. Arg2 is expressed
as a mitochondrial protein in a variety of tissues,
mainly in kidney, prostate, small intestine and the lac-
tating mammary gland. L-Ornithine generated by Arg
can be further metabolized to proline, which is a pre-
cursor of collagen, and polyamines, which participate
in a variety of fundamental cellular functions, such as
proliferation. We observed that treatment with (PhSe)2
resulted in a dose-dependent inhibition of Arg1 activity
in Mph when activated by LPS. Pharmacological inter-
ference with L-arginine metabolism is a promising strat-
egy in the treatment of a variety of diseases. Arginase
expression has been demonstrated in murine inflamma-
tory cell infiltrates in experimental glomerulonephritis,
schistosomiasis, tripanosomiasis, leishmaniasis, auto-
immune encephalomyelitis, asthma, several viral and
bacterial infections, lung fibrosis, sepsis, trauma and
tumors.34 Nevertheless, it cannot be ruled out that the
observed inhibition of Arg activity by (PhSe)2 is caused
by interference in a signaling pathway common to
iNOS induction. El Kasmi et al.30 found that distinct
mechanisms regulate Arg1 expression in different types
of infections. AaMph require the functions of both
STAT6 and C/EBPb but are independent of
MyD88. In contrast, Arg1 can also be directly up-regu-
lated in Mph by pathogen-associated molecular
patterns, like the case of Mycobacterium tuberculosis,
which induces Arg1 in murine Mph through the
TLR-MyD88 pathway and independently of the
STAT6 pathway. It remains to be determined
whether LPS induces Arg1 activity in a similar way to
Mycobacterium and whether (PhSe)2 affects the
upstream signaling pathway or the enzyme activity.
In a recent report, the anti-inflammatory activity of sele-
nium using C57BL/6 bone marrow-derived Mph from
mice fed selenium-deficient and selenium-adequate diets
was described.35 Supplementation with sodium selenite
increased the enzymatic activity of Arg1, and similar
results were obtained with Raw 264.7 cells cultured
with 100 nmol/l selenite. The discrepancies with our
findings could be attributed to the well-known differ-
ences in the arginine metabolism of rodent and murine
Mph.36 In this respect, the same authors also observed
that organic selenium as selenomethionine did not
modify the Arg1 activity, probably as a result of the
inability of selenomethionine to participate in the syn-
thesis of selenoproteins.36 More experiments need to be
done in order to determine how (PhSe)2 modulates the
IL4/IL13 Arg1 inducing pathway.
Regarding the alternative activation, we evaluated
the ability of (PhSe)2 to modulate the dexamethasone
activation of these cells. We found that (PhSe)2 had no
effect on the expression of CD206 and production of
IL-10 of Mph. However, when the cells were treated
with dexamethasone, (PhSe)2 was able to inhibit the
up-regulation of both markers. In accordance with
our results, it was described that selenomethionine
and sodium selenite could inhibit UVB induction of
IL-10 protein in murine keratinocytes.37 These findings
could be helpful in reinforcing the idea that selenium
compounds could be used to prevent immunosupres-
sion triggered by UVB, thereby protecting against
skin tumors. They also led us to speculate that there






















































Figure 7. Effect of (PhSe)2 on the expression of alternative
activation markers in dexamethasone-treated Mph. Peritoneal
Mph were cultured with 1.5 mM dexamethasone to induce the
alternative activation phenotype, and 5 mM (PhSe)2. (A) The cells
were collected and the expression of CD206 was evaluated by
flow cytometry. The expression of CD206 was determined by
the percentage of CD206+ respect to control (n¼ 5). (B) The
cells were cultured for 48 h and the supernatants were collected
and assayed for IL-10 by ELISA. Data are presented as
mean SEM of three independent experiments (n¼ 6).
Significant differences are indicated by *P< 0.05, **P< 0.01.
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IL-10 expression; however, further research needs to be
carried out to clarify this matter.
Conclusions
These results indicate that (PhSe)2 possesses antioxi-
dant activity and that it also functions as an
anti-inflammatory compound in classically-activated
macrophages and can also modulate the alternative
activation phenotype of these cells.
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